Gilles Tamagnan, PhD

Associate Professor Adjunct, Psychiatry

Research & Publications
Biography
News

Coauthors

Selected Publications

IC‐P‐220: CLINICAL UPDATE: 18F‐PI‐2620, A NEXT GENERATION TAU PET AGENT EVALUATED IN SUBJECTS WITH ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSYStephens A, Seibyl J, Mueller A, Barret O, Berndt M, Madonia J, Kroth H, Bullich S, Pfeifer A, Muhs A, Tamagnan G, Marek K, Dinkelborg L. IC‐P‐220: CLINICAL UPDATE: 18F‐PI‐2620, A NEXT GENERATION TAU PET AGENT EVALUATED IN SUBJECTS WITH ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY. Alzheimer's & Dementia 2018, 14: p179-p179. DOI: 10.1016/j.jalz.2018.06.2287.
P1‐400: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTIONTempest P, Ono M, Higuchi M, Shimada H, Suhara T, Zhang M, Tai C, Carroll V, Tamagnan G, Marek K, Barret O, Alagille D, Jang M. P1‐400: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTION. Alzheimer's & Dementia 2018, 14: p455-p455. DOI: 10.1016/j.jalz.2018.06.408.
IC‐P‐082: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTIONTempest P, Ono M, Higuchi M, Shimada H, Suhara T, Tai C, Tamagnan G, Carroll V, Alagille D, Barret O, Marek K, Jang M. IC‐P‐082: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTION. Alzheimer's & Dementia 2018, 14: p71-p71. DOI: 10.1016/j.jalz.2018.06.2146.
T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMANTamagnan G, Barret O, Alagille D, Carroll V, Madonia J, Constantinescu C, SanDiego C, Papin C, Morley T, Russell D, McCarthy T, Zhang L, Gray D, Villalobos A, Lee C, Chen J, Seibyl J, Marek K. T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN. Schizophrenia Bulletin 2018, 44: s176-s176. PMCID: PMC5888516, DOI: 10.1093/schbul/sby016.432.
[IC‐P‐192]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIESMueller A, Kroth H, Schieferstein H, Berndt M, Oden F, Capotosti F, Molette J, Juergens T, Darmency V, Schmitt‐Willich H, Hickman D, Tamagnan G, Pfeifer A, Dinkelborg L, Muhs A, Stephens A. [IC‐P‐192]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES. Alzheimer's & Dementia 2017, 13: p141-p142. DOI: 10.1016/j.jalz.2017.06.2567.
[IC‐P‐198]: FIRST‐IN‐HUMAN PET STUDY WITH 18F‐AM‐PBB3 AND 18F‐PM‐PBB3Shimada H, Kitamura S, Ono M, Kimura Y, Ichise M, Takahata K, Moriguchi S, Kubota M, Ishii T, Takado Y, Seki C, Hirano S, Shinotoh H, Sahara N, Tempest P, Tamagnan G, Seibyl J, Barret O, Alagille D, Zhang M, Kuwabara S, Jang M, Marek K, Suhara T, Higuchi M. [IC‐P‐198]: FIRST‐IN‐HUMAN PET STUDY WITH 18F‐AM‐PBB3 AND 18F‐PM‐PBB3. Alzheimer's & Dementia 2017, 13: p146-p146. DOI: 10.1016/j.jalz.2017.06.2573.
[P3–378]: FIRST‐IN‐HUMAN PET STUDY WITH 18F‐AM‐PBB3 AND 18F‐PM‐PBB3Shimada H, Kitamura S, Maiko O, Kimura Y, Ichise M, Takahata K, Moriguchi S, Kubota M, Ishii T, Takado Y, Seki C, Hirano S, Shinotoh H, Sahara N, Tempest P, Tamagnan G, Seibyl J, Barret O, Alagille D, Zhang M, Kuwabara S, Jang M, Marek K, Suhara T, Higuchi M. [P3–378]: FIRST‐IN‐HUMAN PET STUDY WITH 18F‐AM‐PBB3 AND 18F‐PM‐PBB3. Alzheimer's & Dementia 2017, 13: p1104-p1104. DOI: 10.1016/j.jalz.2017.06.1594.
[P2–381]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIESMueller A, Kroth H, Schieferstein H, Berndt M, Oden F, Capotosti F, Molette J, Juergens T, Darmency V, Schmitt‐Willich H, Hickman D, Tamagnan G, Pfeifer A, Dinkelborg L, Muhs A, Stephens A. [P2–381]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES. Alzheimer's & Dementia 2017, 13: p774-p774. DOI: 10.1016/j.jalz.2017.06.1036.
[IC‐01–05]: FIRST‐IN‐HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18‐F PI‐2620 IN ALZHEIMER's DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLSBarret O, Seibyl J, Stephens A, Madonia J, Alagille D, Mueller A, Berndt M, Kroth H, Capotosti F, Muhs A, Pfeifer A, Tamagnan G, Dinkelborg L, Marek K. [IC‐01–05]: FIRST‐IN‐HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18‐F PI‐2620 IN ALZHEIMER's DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS. Alzheimer's & Dementia 2017, 13: p3-p4. DOI: 10.1016/j.jalz.2017.06.2625.
Effect of Leaving Group Substituents on the Microfluidic Synthesis of [18F]3-Fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile ([18F]FPEB)W. Kabalka G, M. Moore T, R. Akula M, Collier L, Tamagnan G, Papin C, Alagille D. Effect of Leaving Group Substituents on the Microfluidic Synthesis of [18F]3-Fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile ([18F]FPEB). Heterocycles 2017, 95: 807. DOI: 10.3987/com-16-s(s)49.
P4‐351: Evaluation of TAU Burden in a Cross‐Sectional Cohort of Alzheimer’S Disease Subjects Using [18F]GTP1 (GENENTECH TAU PROBE 1)Bohorquez S, Barret O, Tamagnan G, Alagille D, Marik J, Ayalon G, Bengtsson T, de Crespigny A, Jennings D, Seibyl J, Marek K, Weimer R, Kerchner G. P4‐351: Evaluation of TAU Burden in a Cross‐Sectional Cohort of Alzheimer’S Disease Subjects Using [18F]GTP1 (GENENTECH TAU PROBE 1). Alzheimer's & Dementia 2016, 12: p1172-p1172. DOI: 10.1016/j.jalz.2016.07.096.
Imaging Studies with A2A Receptor AntagonistsTavares A, Barret O, Seibyl J, Tamagnan G. Imaging Studies with A2A Receptor Antagonists. 2015, 10: 207-232. DOI: 10.1007/978-3-319-20273-0_11.
O4‐07‐06: Approaches to quantitative analysis of the PET tau radiotracer [18F]AV1451Seibyl J, Barret O, Alagille D, Jennings D, Russell D, Marek K, Tamagnan G. O4‐07‐06: Approaches to quantitative analysis of the PET tau radiotracer [18F]AV1451. Alzheimer's & Dementia 2015, 11: p285-p285. DOI: 10.1016/j.jalz.2015.07.386.
Synthesis of 3‐[18F]Fluoro‐5‐(2‐Pyridinylethynyl)Benzonitrile ([18F]FPEB)Liang S, Yokell D, Jackson R, Rice P, Livni E, Alagille D, Tamagnan G, Collier T, Vasdev N. Synthesis of 3‐[18F]Fluoro‐5‐(2‐Pyridinylethynyl)Benzonitrile ([18F]FPEB). 2015, 41-51. DOI: 10.1002/9781118834114.ch5.
P4‐301: PRECLINICAL AND CLINICAL PROPERTIES OF [123I]ABC577: A NOVEL RADIOIODINATED SPECT AGENT FOR IMAGING B‐AMYLOID IN THE BRAINMaya Y, Okumura Y, Onishi T, Shoyama Y, Barret O, Alagille D, Jennings D, Marek K, Seibyl J, Tamagnan G, Tanaka A, Shirakami Y. P4‐301: PRECLINICAL AND CLINICAL PROPERTIES OF [123I]ABC577: A NOVEL RADIOIODINATED SPECT AGENT FOR IMAGING B‐AMYLOID IN THE BRAIN. Alzheimer's & Dementia 2014, 10: p895-p895. DOI: 10.1016/j.jalz.2014.07.072.
Poster #S67 IN VIVO CHARACTERIZATION OF THE PDE10A PET TRACER [18F]MNI-659Tamagnan G, Barret O, Papin C, Alagille D, Thomae D, Baldwin R, Marek K, Seibyl J. Poster #S67 IN VIVO CHARACTERIZATION OF THE PDE10A PET TRACER [18F]MNI-659. Schizophrenia Research 2014, 153: s112. DOI: 10.1016/s0920-9964(14)70346-9.
Erratum to “Potent mGluR5 antagonists: Pyridyl and thiazolyl-ethynyl-3,5-disubstituted-phenyl series” [Bioorg. Med. Chem. Lett. 21 (2011) 3243–3247]Alagille D, DaCosta H, Chen Y, Hemstapat K, Rodriguez A, Baldwin R, Conn P, Tamagnan G. Erratum to “Potent mGluR5 antagonists: Pyridyl and thiazolyl-ethynyl-3,5-disubstituted-phenyl series” [Bioorg. Med. Chem. Lett. 21 (2011) 3243–3247]. Bioorganic & Medicinal Chemistry Letters 2012, 22: 2130. DOI: 10.1016/j.bmcl.2012.01.054.
ChemInform Abstract: 2‐Arylimidazo[2,1‐b]benzothiazoles: A New Family of Amyloid Binding Agents with Potential for PET and SPECT Imaging of Alzheimer′s Brain.Alagille D, DaCosta H, Baldwin R, Tamagnan G. ChemInform Abstract: 2‐Arylimidazo[2,1‐b]benzothiazoles: A New Family of Amyloid Binding Agents with Potential for PET and SPECT Imaging of Alzheimer′s Brain. ChemInform 2011, 42: no-no. DOI: 10.1002/chin.201139199.
P2‐035: Preliminary evaluation of the amyloid PET Radioligand [18F]MK‐3328 in Alzheimer's Disease patientsSanabria‐Bohorquez S, Hostetler E, Van Laere K, Koole M, Bormans G, Serdons K, de Hoon J, Vandenberghe R, Versijpt J, De Lepeleire I, Reynders T, Tamagnan G, Marek K, Seibyl J, Jennings D, Barret O, Koren A, Rosen L, Hargreaves R, Evelhoch J, Sur C, Forman M. P2‐035: Preliminary evaluation of the amyloid PET Radioligand [18F]MK‐3328 in Alzheimer's Disease patients. Alzheimer's & Dementia 2011, 7: s319-s319. DOI: 10.1016/j.jalz.2011.05.925.
P02-339 - Spect imaging of the serotonin transporter using a novel ligand - 123-I mZIENT - in human subjects - a dosimetry and biodisortribution studyKrishnadas R, Nicol A, Champion S, Pimlott S, Stehouwer J, Tamagnan G, Goodman M, Hadley D. P02-339 - Spect imaging of the serotonin transporter using a novel ligand - 123-I mZIENT - in human subjects - a dosimetry and biodisortribution study. European Psychiatry 2011, 26: 935. DOI: 10.1016/s0924-9338(11)72640-2.
Chapter 3Alagille D, Baldwin R, Tamagnan G. Chapter 3. 2011, 49-143. DOI: 10.1039/9781849732918-00049.
PET evaluation of the TSPO ligands [F-18]FEPPA, [F-18]PRB06, and [F-18]PBR111 in nonhuman primateCarson R, Weinzimmer D, Koren A, Alagille D, Fowles K, Ashworth S, Seibyl J, Katsifis A, Gunn R, Rabiner E, Tang S, Tamagnan G. PET evaluation of the TSPO ligands [F-18]FEPPA, [F-18]PRB06, and [F-18]PBR111 in nonhuman primate. NeuroImage 2010, 52: s147. DOI: 10.1016/j.neuroimage.2010.04.121.
Kinetic modeling of the mGluR5 tracer [18F]F-FPEB in humansSullivan J, Lim K, Labree D, Lin S, McCarthy T, Seibyl J, Tamagnan G, Huang Y, Carson R, Morris E, Ding Y. Kinetic modeling of the mGluR5 tracer [18F]F-FPEB in humans. NeuroImage 2010, 52: s169-s170. DOI: 10.1016/j.neuroimage.2010.04.138.
Quantitation of glutamate mGluR5 receptor with 18F-FPEB PET in humansBarret O, Tamagnan G, Batis J, Jennings D, Zubal G, Russel D, Marek K, Seiby J. Quantitation of glutamate mGluR5 receptor with 18F-FPEB PET in humans. NeuroImage 2010, 52: s202. DOI: 10.1016/j.neuroimage.2010.04.164.
Test/retest reproducibility of iodine-123-MNI308 in nonhuman primatesBatis J, Barret O, Marek K, Tamagnan G, Zubal G, Kordower J, Seibyl J. Test/retest reproducibility of iodine-123-MNI308 in nonhuman primates. NeuroImage 2010, 52: s207. DOI: 10.1016/j.neuroimage.2010.04.169.
P.1.025 Molecular imaging of beta-2 subunit containing nicotinic acetylcholine receptors in major depressive disorderSaricicek A, Esterlis I, Ruf B, Maloney K, Muralidharan A, Seibyl J, Tamagnan G, Bois F, Staley J, Bhagwagar Z. P.1.025 Molecular imaging of beta-2 subunit containing nicotinic acetylcholine receptors in major depressive disorder. European Neuropsychopharmacology 2010, 20: s22. DOI: 10.1016/s0924-977x(10)70027-4.
Third Annual Huntington Disease Clinical Research SymposiumDubinsky R, Roberson J, Battaglia G, Cannella M, Riozzi B, Orobello S, Maat-Schieman M, Aronica E, Busceti C, Ciarmiello A, Alberti S, Sassone J, Sipione S, Bruno V, Frati L, Nicoletti F, Squitieri F, Rao A, Gordon A, Marder K, Nolta J, Anderson K, Gruber-Baldini A, Medalie J, Reich S, Fishman P, Robottom B, Weiner W, Shulman L, Langbehn D, Paulsen J, PREDICT-HD Investigators of the Huntington Study Group, Witten C, Cox M, Feigin A, Napolitano B, Goh A, Yastrubetskaya O, Chiu E, Cloud L, Helmers S, Jones R, Factor S, Emory C, Kegelmeyer D, Kostyk S, Fritz N, Kloos A, Lessig S, Goldstein J, Corey-Bloom J, Simonelli M, Martino T, Colonnese C, Callaghan J, Arran N, Boisse M, Coleman A, Dar Santos R, Dumas E, Hart E, Justo D, Read J, Say M, Van Den Bogaard S, Durr A, Leavitt B, Roos R, Tabrizi S, Bourdet C, van Duijn E, Craufurd D, TRACK-FID Investigators, Evans K, Vaccarino A, TRACK-HD Investigators, Aylward E, Nopoulos P, Ross C, Pierson R, Mills J, Magnotta V, Johnson H, PREDICT-HD Investigators and Coordinators of the Huntington Study Group, Mitchell A, Cortes J, Dahmubed A, Krakauer J, Mazzoni P, Russell D, Jennings D, Tamagnan G, Seibyl J, Koren A, Zubal G, Marek K, Goodman L, Carnes R, Giuliano J, Vetter L, MacDonald M, Lee J, Seong I, Fossale E, Anderson M, Wheeler V, Gusella J, Johnson J, Yu T, Jones D, Chan A, Richardson K, McCusker E, Loy C, Griffith J, Paulsen J, PREDICT-HD Investigators of the Huntington Study Group, Waters S, Tedroff J, Kieburtz K, Krogh P, Buusman A, Rembratt Å, Dorey J, Lamure M, Toumi M, von der Schulenburg J, Pettersson F, Dyhring T, Sonesson C, Waters N, Pontén H, Erwin C, Williams J, Juhl A, Investigators of the Huntington Study Group, Huntington Study Group PHAROS Investigators, Adams W, Byars J, O’Rourke J, Flynn A, Fiedorowicz J, Duff K, Leserman A, Beglinger L, Smith M, Stout J, Queller S, Rao S, Zimbelman J, Groves M, Guttman M, Wexler E, Perlman S, Burgunder J, Rosenblatt A, van Kammen D, PREDICT-HD Investigators of the Huntington Study Group. Third Annual Huntington Disease Clinical Research Symposium. Neurotherapeutics 2010, 7: 135-147. DOI: 10.1007/bf03215660.
Poster 14: Evaluation of Novel Radiotracers Targeting Non-Dopaminergic Striatal Biomarkers in HD: 18F-FPEB and PET Imaging for Metabotropic Glutamate Receptor Type 5 (mGluR5) Expression in Healthy Subjects and Subjects with Huntington Disease (HD)Russell D, Jennings D, Tamagnan G, Seibyl J, Koren A, Zubal G, Marek K. Poster 14: Evaluation of Novel Radiotracers Targeting Non-Dopaminergic Striatal Biomarkers in HD: 18F-FPEB and PET Imaging for Metabotropic Glutamate Receptor Type 5 (mGluR5) Expression in Healthy Subjects and Subjects with Huntington Disease (HD). Neurotherapeutics 2010, 7: 142. DOI: 10.1016/j.nurt.2009.09.016.
IC‐P‐127: Multicenter quantitative amyloid PET imaging in phase III alzheimer therapeutic trials: Strategies for achieving good imaging practices in the support of drug developmentSeibyl J, Zubal G, Tamagnan G, Marek K. IC‐P‐127: Multicenter quantitative amyloid PET imaging in phase III alzheimer therapeutic trials: Strategies for achieving good imaging practices in the support of drug development. Alzheimer's & Dementia 2009, 5: p52-p52. DOI: 10.1016/j.jalz.2009.05.099.
P2‐016: Multicenter quantitative amyloid PET imaging in Phase III Alzheimer's therapeutic trials: Strategies for achieving good imaging practices in the support of drug developmentSeibyl J, Zubal G, Tamagnan G, Marek K. P2‐016: Multicenter quantitative amyloid PET imaging in Phase III Alzheimer's therapeutic trials: Strategies for achieving good imaging practices in the support of drug development. Alzheimer's & Dementia 2009, 5: p265-p265. DOI: 10.1016/j.jalz.2009.04.325.
Imagerie moléculaire du transporteur vésiculaire de l’acétylcholine (VACh) par le [123I]-5-iodobenzovézamicol dans la démence de type Alzheimer (DTA)Quetu F, Prunier C, Pogam L, Hommet C, Tamagnan G, Allard M, Guilloteau D, Seibyl J, Baulieu J. Imagerie moléculaire du transporteur vésiculaire de l’acétylcholine (VACh) par le [123I]-5-iodobenzovézamicol dans la démence de type Alzheimer (DTA). Nuklearmedizin - NuclearMedicine 2009, 33: 338-351. DOI: 10.1016/j.mednuc.2008.12.005.
IC‐P3‐215: Automated image processing algorithms for evaluating novel 123‐Iodine‐labeled beta‐amyloid imaging agents MNI‐187 and MNI‐308 in Alzheimer's patientsSeibyl J, Marek K, Jennings D, Tamagnan G, Zubal G. IC‐P3‐215: Automated image processing algorithms for evaluating novel 123‐Iodine‐labeled beta‐amyloid imaging agents MNI‐187 and MNI‐308 in Alzheimer's patients. Alzheimer's & Dementia 2008, 4: t91-t92. DOI: 10.1016/j.jalz.2008.05.160.
P4‐346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's diseaseSiemers E, Friedrich S, Dean R, Sethuraman G, DeMattos R, Jennings D, Tamagnan G, Marek K, Seibyl J. P4‐346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease. Alzheimer's & Dementia 2008, 4: t774-t774. DOI: 10.1016/j.jalz.2008.05.2416.
6‐[123I]Iodo‐2‐[[4‐(2‐methoxyphenyl) piperazin‐1‐yl]methyl]imidazo[1,2‐a]pyridine as potential SPECT agent for imaging dopamine D4 receptor: synthesis and in vivo evaluation in a nonhuman primateAlagille D, Koren A, Kudej G, Staley J, Cosgrove K, Seibyl J, Tamagnan G. 6‐[123I]Iodo‐2‐[[4‐(2‐methoxyphenyl) piperazin‐1‐yl]methyl]imidazo[1,2‐a]pyridine as potential SPECT agent for imaging dopamine D4 receptor: synthesis and in vivo evaluation in a nonhuman primate. Journal Of Labelled Compounds And Radiopharmaceuticals 2008, 51: 202-206. DOI: 10.1002/jlcr.1500.
Automated radio-tracer evaluationZubal G, Wisniewski G, Marek K, Tamagnan G, Seibyl J. Automated radio-tracer evaluation. NeuroImage 2008, 41: t107. DOI: 10.1016/j.neuroimage.2008.04.076.
Nicotinic receptor dysfunction in major depressive disorder: A trait vulnerability marker of depressionBhagwagar Z, Esterlis I, Ruf B, Muralidharan A, Lorberg B, Saricicek A, Bois F, Tamagnan G, Seibyl J, Staley J. Nicotinic receptor dysfunction in major depressive disorder: A trait vulnerability marker of depression. NeuroImage 2008, 41: t176. DOI: 10.1016/j.neuroimage.2008.04.143.
SPECT imaging of [123I]5-IA-85380 binding to beta2-nicotinic acetylcholine receptors in healthy smokers: Assessment of nondisplaceable uptakeBatis J, Esterlis I, Bois F, Cosgrove K, Stiklus S, Kloczynski T, McKee S, Jatlow P, O'Malley S, Seibyl J, Tamagnan G, Van Dyck C, Staley J. SPECT imaging of [123I]5-IA-85380 binding to beta2-nicotinic acetylcholine receptors in healthy smokers: Assessment of nondisplaceable uptake. NeuroImage 2008, 41: t175. DOI: 10.1016/j.neuroimage.2008.04.142.
Single nucleotide polymorphisms of ANKK1 and CHRNA4: Influence on nicotinic acetylcholine receptor availability in nonsmokers measured using [123I]5-IA-85380 SPECTBatis J, Yang B, Cosgrove K, Bois F, Esterlis I, Stiklus S, Kloczynski T, Perry E, Seibyl J, Tamagnan G, Van Dyck C, Gelernter J, Staley J. Single nucleotide polymorphisms of ANKK1 and CHRNA4: Influence on nicotinic acetylcholine receptor availability in nonsmokers measured using [123I]5-IA-85380 SPECT. NeuroImage 2008, 41: t174. DOI: 10.1016/j.neuroimage.2008.04.141.
Sex differences in nicotinic acetylcholine receptor availability in heavy alcohol drinkersEsterlis I, Bois F, Cosgrove K, Stiklus S, Perry E, Tamagnan G, Seibyl J, Krystal J, Staley J. Sex differences in nicotinic acetylcholine receptor availability in heavy alcohol drinkers. NeuroImage 2008, 41: t183. DOI: 10.1016/j.neuroimage.2008.04.150.
Regulation of β2-nAChR during acute and prolonged abstinence from tobacco Smoking: A [123I]5-IA-85380 SPECT imaging studyCosgrove K, Batis J, Bois F, Esterlis I, Stiklus S, Kloczynski T, Maciejewski P, Krishnan-Sarin S, O'Malley S, Perry E, Tamagnan G, Seibyl J, Staley J. Regulation of β2-nAChR during acute and prolonged abstinence from tobacco Smoking: A [123I]5-IA-85380 SPECT imaging study. NeuroImage 2008, 41: t180. DOI: 10.1016/j.neuroimage.2008.04.147.
[123I]5-IA-85380 SPECT imaging nicotine occupancy of brain β2-nicotinic acetylcholine receptors after smoking low nicotine and nicotine-free cigarettesEsterlis I, Batis J, Cosgrove K, Bois F, McKee S, Kloczynski T, Stiklus S, O'Malley S, Perry E, Tamagnan G, Seibyl J, Staley J. [123I]5-IA-85380 SPECT imaging nicotine occupancy of brain β2-nicotinic acetylcholine receptors after smoking low nicotine and nicotine-free cigarettes. NeuroImage 2008, 41: t182. DOI: 10.1016/j.neuroimage.2008.04.149.
P‐046: [I‐123] IMPY imaging in Alzheimer's disease and healthy controlsMarek K, Jennings D, Tamagnan G, Koren A, Skovronsky D, Seibyl J. P‐046: [I‐123] IMPY imaging in Alzheimer's disease and healthy controls. Alzheimer's & Dementia 2007, 3: s112-s112. DOI: 10.1016/j.jalz.2007.04.262.
Radiosynthesis of 3‐(3‐[18F]fluoropropoxy)‐4‐(benzyloxy)‐N‐[(1‐dimethylaminocyclopentyl)methyl]‐5‐methoxybenzamide, a potential PET radiotracer for the glycine transporter GlyT‐2Tian H, Vogel R, Amici L, Tamagnan G, Baldwin R. Radiosynthesis of 3‐(3‐[18F]fluoropropoxy)‐4‐(benzyloxy)‐N‐[(1‐dimethylaminocyclopentyl)methyl]‐5‐methoxybenzamide, a potential PET radiotracer for the glycine transporter GlyT‐2. Journal Of Labelled Compounds And Radiopharmaceuticals 2006, 49: 1247-1258. DOI: 10.1002/jlcr.1145.
Synthesis and Monoamine Transporter Affinity of New 2β‐Carbomethoxy‐3β‐[aryl or heteroaryl]phenyltropanes.Tamagnan G, Alagille D, Fu X, Kula N, Baldessarini R, Innis R, Baldwin R. Synthesis and Monoamine Transporter Affinity of New 2β‐Carbomethoxy‐3β‐[aryl or heteroaryl]phenyltropanes. ChemInform 2006, 37: no-no. DOI: 10.1002/chin.200614200.
Longitudinal assessment of beta2-nicotinic acetylcholine receptor availability in abstinent smokers: A [I-123]5-IA-85380 SPECT imaging studyCosgrove K, Frohlich E, Krishnan-Sarin S, O'Malley S, Bois F, Tamagnan G, Seibyl J, Staley J. Longitudinal assessment of beta2-nicotinic acetylcholine receptor availability in abstinent smokers: A [I-123]5-IA-85380 SPECT imaging study. NeuroImage 2006, 31: t155. DOI: 10.1016/j.neuroimage.2006.04.138.
[I-123] 5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy and schizophrenic smokersStaley J, Tellioglu T, Bois F, Palazzo C, McGuire-Schwartz N, Cosgrove K, van Dyck C, Tamagnan G, Seibyl J, Krystal J, D'Souza D. [I-123] 5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy and schizophrenic smokers. NeuroImage 2006, 31: t154. DOI: 10.1016/j.neuroimage.2006.04.137.
INER, a subnanomolar affinity ligand for the norepinephrine transporter: In vivo characterization in subhuman primatesTamagnan G, Koren A, Staley J, Cosgrove K, Megyola C, Marek K, Seibyl J. INER, a subnanomolar affinity ligand for the norepinephrine transporter: In vivo characterization in subhuman primates. NeuroImage 2006, 31: t137. DOI: 10.1016/j.neuroimage.2006.04.121.
Synthesis, Radiosynthesis, and Biological Evaluation of Carbon-11 and Fluorine-18 (N-Fluoroalkyl) Labeled 2β-Carbomethoxy-3β-(4'-(3-furyl)phenyl)tropanes and -nortropanes: Candidate Radioligands for in Vivo Imaging of the Serotonin Transporter with Positron Emission TomographyStehouwer J, Plisson C, Jarkas N, Zeng F, Voll R, Williams L, Martarello L, Votaw J, Tamagnan G, Goodman M. Synthesis, Radiosynthesis, and Biological Evaluation of Carbon-11 and Fluorine-18 (N-Fluoroalkyl) Labeled 2β-Carbomethoxy-3β-(4'-(3-furyl)phenyl)tropanes and -nortropanes: Candidate Radioligands for in Vivo Imaging of the Serotonin Transporter with Positron Emission Tomography. Journal Of Medicinal Chemistry 2005, 48: 7080-7083. PMID: 16250668, DOI: 10.1021/jm0504095.
A Close Structural Analog of 2-Methyl-6-(phenylethynyl)-pyridine Acts as a Neutral Allosteric Site Ligand on Metabotropic Glutamate Receptor Subtype 5 and Blocks the Effects of Multiple Allosteric ModulatorsRodriguez A, Nong Y, Sekaran N, Alagille D, Tamagnan G, Conn P. A Close Structural Analog of 2-Methyl-6-(phenylethynyl)-pyridine Acts as a Neutral Allosteric Site Ligand on Metabotropic Glutamate Receptor Subtype 5 and Blocks the Effects of Multiple Allosteric Modulators. Molecular Pharmacology 2005, 68: 1793-1802. PMID: 16155210, DOI: 10.1124/mol.105.016139.
Asymmetric Synthesis of (+)‐(S,S)‐Reboxetine via a New (S)‐2‐(Hydroxymethyl)morpholine Preparation.Brenner E, Baldwin R, Tamagnan G. Asymmetric Synthesis of (+)‐(S,S)‐Reboxetine via a New (S)‐2‐(Hydroxymethyl)morpholine Preparation. ChemInform 2005, 36: no-no. DOI: 10.1002/chin.200530149.
Synthesis and Monoamine Transporter Affinity of New 2β‐Carbomethoxy‐3β‐[4‐(substituted thiophenyl)]phenyltropanes: Discovery of a Selective SERT Antagonist with Picomolar Potency.Tamagnan G, Alagille D, Fu X, Kula N, Baldessarini R, Innis R, Baldwin R. Synthesis and Monoamine Transporter Affinity of New 2β‐Carbomethoxy‐3β‐[4‐(substituted thiophenyl)]phenyltropanes: Discovery of a Selective SERT Antagonist with Picomolar Potency. ChemInform 2005, 36: no-no. DOI: 10.1002/chin.200527194.
Functionalization at Position 3 of the Phenyl Ring of the Potent mGluR5 Noncompetitive Antagonists MPEP.Alagille D, Baldwin R, Roth B, Wroblewski J, Grajkowska E, Tamagnan G. Functionalization at Position 3 of the Phenyl Ring of the Potent mGluR5 Noncompetitive Antagonists MPEP. ChemInform 2005, 36: no-no. DOI: 10.1002/chin.200525143.
One‐Step Synthesis of 2‐Arylbenzothiazole (“BTA”) and ‐benzoxazole Precursors for in vivo Imaging of β‐Amyloid Plaques.Alagille D, Baldwin R, Tamagnan G. One‐Step Synthesis of 2‐Arylbenzothiazole (“BTA”) and ‐benzoxazole Precursors for in vivo Imaging of β‐Amyloid Plaques. ChemInform 2005, 36: no-no. DOI: 10.1002/chin.200524120.
One-step synthesis of 2-arylbenzothiazole (‘BTA’) and -benzoxazole precursors for in vivo imaging of β-amyloid plaquesAlagille D, Baldwin R, Tamagnan G. One-step synthesis of 2-arylbenzothiazole (‘BTA’) and -benzoxazole precursors for in vivo imaging of β-amyloid plaques. Tetrahedron Letters 2005, 46: 1349-1351. DOI: 10.1016/j.tetlet.2004.12.111.
Functionalization at position 3 of the phenyl ring of the potent mGluR5 noncompetitive antagonists MPEPAlagille D, Baldwin R, Roth B, Wroblewski J, Grajkowska E, Tamagnan G. Functionalization at position 3 of the phenyl ring of the potent mGluR5 noncompetitive antagonists MPEP. Bioorganic & Medicinal Chemistry Letters 2005, 15: 945-949. PMID: 15686891, DOI: 10.1016/j.bmcl.2004.12.047.
Asymmetric Synthesis of (+)-(S,S)-Reboxetine via a New (S)-2-(Hydroxymethyl)morpholine PreparationBrenner E, Baldwin R, Tamagnan G. Asymmetric Synthesis of (+)-(S,S)-Reboxetine via a New (S)-2-(Hydroxymethyl)morpholine Preparation. Organic Letters 2005, 7: 937-939. PMID: 15727479, DOI: 10.1021/ol050059g.
Synthesis and receptor assay of aromatic–ethynyl–aromatic derivatives with potent mGluR5 antagonist activityAlagille D, Baldwin R, Roth B, Wroblewski J, Grajkowska E, Tamagnan G. Synthesis and receptor assay of aromatic–ethynyl–aromatic derivatives with potent mGluR5 antagonist activity. Bioorganic & Medicinal Chemistry 2005, 13: 197-209. PMID: 15582465, DOI: 10.1016/j.bmc.2004.09.042.
Total Synthesis of the Marine Cytotoxic Caulibugulones A—D.Alagille D, Baldwin R, Tamagnan G. Total Synthesis of the Marine Cytotoxic Caulibugulones A—D. ChemInform 2004, 35: no-no. DOI: 10.1002/chin.200447187.
Synthesis and Monoamine Transporter Affinity of 3′‐Analogues of 2‐β‐Carbomethoxy‐3‐β‐(4′‐iodophenyl)tropane (β‐CIT).Bois F, Baldwin R, Kula N, Baldessarini R, Innis R, Tamagnan G. Synthesis and Monoamine Transporter Affinity of 3′‐Analogues of 2‐β‐Carbomethoxy‐3‐β‐(4′‐iodophenyl)tropane (β‐CIT). ChemInform 2004, 35: no-no. DOI: 10.1002/chin.200435205.
Total synthesis of the marine cytotoxic caulibugulones A–DAlagille D, Baldwin R, Tamagnan G. Total synthesis of the marine cytotoxic caulibugulones A–D. Tetrahedron Letters 2004, 45: 6179-6181. DOI: 10.1016/j.tetlet.2004.06.007.
Crystal structure of 2-(3-methoxyphenylethynyl)-6-methylpyridine, C15H13NO, M-MPEP – a mGluR5 antagonistAlagille D, Baldwin R, Incarvito C, Tamagnan G. Crystal structure of 2-(3-methoxyphenylethynyl)-6-methylpyridine, C15H13NO, M-MPEP – a mGluR5 antagonist. Zeitschrift Für Kristallographie - Crystalline Materials 2004, 219: 187-188. DOI: 10.1524/ncrs.2004.219.2.187.
Synthesis and monoamine transporter affinity of 3′-analogs of 2-β-carbomethoxy-3-β-(4′-iodophenyl)tropane (β-CIT)Bois F, Baldwin R, Kula N, Baldessarini R, Innis R, Tamagnan G. Synthesis and monoamine transporter affinity of 3′-analogs of 2-β-carbomethoxy-3-β-(4′-iodophenyl)tropane (β-CIT). Bioorganic & Medicinal Chemistry Letters 2004, 14: 2117-2120. PMID: 15080991, DOI: 10.1016/j.bmcl.2004.02.043.
Crystal structure of 2-(3-methoxyphenylethynyl)-6-methylpyridine, C15H13NO, M-MPEP- a mGluR5 antagonistAlagille D, Baldwin R, Incarvito C, Tamagnan G. Crystal structure of 2-(3-methoxyphenylethynyl)-6-methylpyridine, C15H13NO, M-MPEP- a mGluR5 antagonist. Zeitschrift Für Kristallographie - Crystalline Materials 2004, 219: 197-198. DOI: 10.1524/ncrs.2004.219.14.197.
Synthesis of a new precursor to the nicotinic receptor tracer 5-IA-85380 precursor using trimethylsilyl iodide as deblocking agentBrenner E, Baldwin R, Tamagnan G. Synthesis of a new precursor to the nicotinic receptor tracer 5-IA-85380 precursor using trimethylsilyl iodide as deblocking agent. Tetrahedron Letters 2004, 45: 3607-3610. DOI: 10.1016/j.tetlet.2004.03.061.
Radiosynthesis of [18F] N-(3-Fluoropropyl)-2-β-Carbomethoxy-3-β-(4-Bromophenyl) Nortropane and the regional brain uptake in non human primate using PETChaly T, Baldwin R, Neumeyer J, Hellman M, Dhawan V, Garg P, Tamagnan G, Staley J, Al-Tikriti M, Hou Y, Zoghbi S, Gu X, Zong R, Eidelberg D. Radiosynthesis of [18F] N-(3-Fluoropropyl)-2-β-Carbomethoxy-3-β-(4-Bromophenyl) Nortropane and the regional brain uptake in non human primate using PET. Nuclear Medicine And Biology 2004, 31: 125-131. PMID: 14741577, DOI: 10.1016/s0969-8051(03)00110-0.
Synthesis and affinity of a possible byproduct of electrophilic radiolabeling of [123I]IBZMBaldwin R, Fu X, Kula N, Baldessarini R, Amici L, Innis R, Tamagnan G. Synthesis and affinity of a possible byproduct of electrophilic radiolabeling of [123I]IBZM. Bioorganic & Medicinal Chemistry Letters 2003, 13: 4015-4017. PMID: 14592497, DOI: 10.1016/j.bmcl.2003.08.063.
Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5‐I‐A‐85380Fujita M, Al‐Tikriti M, Tamagnan G, Zoghbi S, Bozkurt A, Baldwin R, Innis R. Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5‐I‐A‐85380. Synapse 2003, 48: 116-122. PMID: 12645036, DOI: 10.1002/syn.10194.
Rearrangement of a Mesylate Tropane Intermediate in Nucleophilic Substitution Reactions. Synthesis of Aza-Bicyclo[3.2.1]octane and Aza-Bicyclo[3.2.2]nonane Ethers, † Imides, and AminesOgier L, Turpin F, Baldwin R, Riché F, Law H, Innis R, Tamagnan G. Rearrangement of a Mesylate Tropane Intermediate in Nucleophilic Substitution Reactions. Synthesis of Aza-Bicyclo[3.2.1]octane and Aza-Bicyclo[3.2.2]nonane Ethers, † Imides, and Amines. The Journal Of Organic Chemistry 2002, 67: 3637-3642. PMID: 12027674, DOI: 10.1021/jo010973x.
Synthesis, Receptor Potency, and Selectivity of Halogenated Diphenylpiperidines as Serotonin 5-HT2A Ligands for PET or SPECT Brain ImagingFu X, Tan P, Kula N, Baldessarini R, Tamagnan G, Innis R, Baldwin R. Synthesis, Receptor Potency, and Selectivity of Halogenated Diphenylpiperidines as Serotonin 5-HT2A Ligands for PET or SPECT Brain Imaging. Journal Of Medicinal Chemistry 2002, 45: 2319-2324. PMID: 12014970, DOI: 10.1021/jm0200411.
Synthesis of Cyclopentadienyltricarbonyl Rhenium Phenyltropanes by Double Ligand Transfer: Organometallic Ligands for the Dopamine TransporterCesati R, Tamagnan G, Baldwin R, Zoghbi S, Innis R, Kula N, Baldessarini R, Katzenellenbogen J. Synthesis of Cyclopentadienyltricarbonyl Rhenium Phenyltropanes by Double Ligand Transfer: Organometallic Ligands for the Dopamine Transporter. Bioconjugate Chemistry 2001, 13: 29-39. PMID: 11792176, DOI: 10.1021/bc010011x.
Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123I]5-I-A-85380 in healthy human subjectsFujita M, Seibyl J, Vaupel B, Tamagnan G, Early M, Zoghbi S, Baldwin R, Horti A, Koren A, Mukhin A, Khan S, Bozkurt A, Kimes A, London E, Innis R. Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123I]5-I-A-85380 in healthy human subjects. European Journal Of Nuclear Medicine And Molecular Imaging 2001, 29: 183-190. PMID: 11926380, DOI: 10.1007/s00259-001-0695-z.
Sex differences in [123I]β‐CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokersStaley J, Krishnan‐Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl J, Maciejewski P, O'Malley S, Innis R. Sex differences in [123I]β‐CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 2001, 41: 275-284. PMID: 11494398, DOI: 10.1002/syn.1084.
Synthesis, radiolabeling and preliminary evaluation of 2β‐Carbomethoxy‐3β‐(3”‐methoxypyridyl)tropane (YP186), a potential radioligand for the serotonin transporterHou Y, Fu X, Al‐Tikriti M, Garg S, Korde A, Baldwin R, Kula N, Staley J, Innis R, Seibyl J, Baldessarini R, Garg P, Tamagnan G. Synthesis, radiolabeling and preliminary evaluation of 2β‐Carbomethoxy‐3β‐(3”‐methoxypyridyl)tropane (YP186), a potential radioligand for the serotonin transporter. Journal Of Labelled Compounds And Radiopharmaceuticals 2001, 44: s185-s187. DOI: 10.1002/jlcr.2580440164.
Measurement of plasma metabolites of (S)-5-[123I]iodo-3- (2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primatesZoghbi S, Tamagnan G, Fujita M, Baldwin R, Al-Tikriti M, Amici L, Seibyl J, Innis R. Measurement of plasma metabolites of (S)-5-[123I]iodo-3- (2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates. Nuclear Medicine And Biology 2001, 28: 91-96. PMID: 11182569, DOI: 10.1016/s0969-8051(00)00188-8.
ChemInform Abstract: Synthesis and Monoamine Transporter Affinity of 2β‐Carbomethoxy‐3β‐(2′′‐, 3′′‐, or 4′′‐substituted) Biphenyltropanes.Tamagnan G, Baldwin R, Kula N, Baldessarini R, Innis R. ChemInform Abstract: Synthesis and Monoamine Transporter Affinity of 2β‐Carbomethoxy‐3β‐(2′′‐, 3′′‐, or 4′′‐substituted) Biphenyltropanes. ChemInform 2000, 31: no-no. DOI: 10.1002/chin.200046223.
Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT.Fujita M, Tamagnan G, Zoghbi S, Al-Tikriti M, Baldwin R, Seibyl J, Innis R. Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT. Journal Of Nuclear Medicine 2000, 41: 1552-60. PMID: 10994738.
Synthesis and monoamine transporter affinity of 2β-carbomethoxy-3β-(2″-, 3″- or 4″-substituted) biphenyltropanesTamagnan G, Baldwin R, Kula N, Baldessarini R, Innis R. Synthesis and monoamine transporter affinity of 2β-carbomethoxy-3β-(2″-, 3″- or 4″-substituted) biphenyltropanes. Bioorganic & Medicinal Chemistry Letters 2000, 10: 1783-1785. PMID: 10969967, DOI: 10.1016/s0960-894x(00)00317-6.
SPECT imaging with the D4 receptor antagonist L-750,667 in nonhuman primate brainStaley J, Tamagnan G, Baldwin R, Fujita M, Tikriti M, Eshima L, Thornback J, Roe D, Lu L, Seibyl J, Innis R. SPECT imaging with the D4 receptor antagonist L-750,667 in nonhuman primate brain. Nuclear Medicine And Biology 2000, 27: 547-556. PMID: 11056368, DOI: 10.1016/s0969-8051(00)00129-3.
Cyclopentadienyltricarbonylrheniumbenzazepines: synthesis and binding affinityTamagnan G, Baldwin R, Kula N, Baldessarini R, Innis R. Cyclopentadienyltricarbonylrheniumbenzazepines: synthesis and binding affinity. Bioorganic & Medicinal Chemistry Letters 2000, 10: 1113-1115. PMID: 10843230, DOI: 10.1016/s0960-894x(00)00185-2.
5-Iodo-A-85380, an α4β2 Subtype-Selective Ligand for Nicotinic Acetylcholine ReceptorsMukhin A, Gündisch D, Horti A, Koren A, Tamagnan G, Kimes A, Chambers J, Vaupel D, King S, Picciotto M, Innis R, London E. 5-Iodo-A-85380, an α4β2 Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors. Molecular Pharmacology 2000, 57: 642-649. PMID: 10692507, DOI: 10.1124/mol.57.3.642.
Nonisotopic surrogates for technetium as ligands for monoamine transporters.Tamagnan G, Gao Y, Xu L, Kula N, Baldessarini R, Neumeyer J. Nonisotopic surrogates for technetium as ligands for monoamine transporters. Advances In Neurology 1999, 80: 99-103. PMID: 10410707.
Novel Phenyltropanes: Affinity to Monoamine Transporters in Rat ForebrainNeumeyer J, Baldessarini R, Kula N, Tamagnan G. Novel Phenyltropanes: Affinity to Monoamine Transporters in Rat Forebrain. 1998, 49: 739-745. DOI: 10.1007/978-1-4615-5337-3_105.
N-Phthalimidoalkyl derivatives of 2β-carbomethoxy-3β-(4′-iodophenyl)tropane (β-CIT): Brain monoamine transporter affinityTamagnan G, Neumeyer J, Gao Y, Wang S, Kula N, Baldessarini R. N-Phthalimidoalkyl derivatives of 2β-carbomethoxy-3β-(4′-iodophenyl)tropane (β-CIT): Brain monoamine transporter affinity. Bioorganic & Medicinal Chemistry Letters 1997, 7: 337-340. DOI: 10.1016/s0960-894x(97)00009-7.
Radiosynthesis of [18F] N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane and the first human study with positron emission tomographyChaly T, Dhawan V, Kazumata K, Antonini A, Margouleff C, Dahl J, Belakhlef A, Margouleff D, Yee A, Wang S, Tamagnan G, Neumeyer J, Eidelberg D. Radiosynthesis of [18F] N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane and the first human study with positron emission tomography. Nuclear Medicine And Biology 1996, 23: 999-1004. PMID: 9004288, DOI: 10.1016/s0969-8051(96)00155-2.
ChemInform Abstract: Synthesis of β‐CIT‐BAT, a Potential 99mTc Imaging Ligand for Dopamine Transporter.TAMAGNAN G, GAO Y, BALDWIN R, ZOGHBI S, NEUMEYER J. ChemInform Abstract: Synthesis of β‐CIT‐BAT, a Potential 99mTc Imaging Ligand for Dopamine Transporter. ChemInform 1996, 27: no-no. DOI: 10.1002/chin.199641159.
Synthesis of β-CIT-BAT, a potential technetium-99m imaging ligand for dopamine transporterTamagnan G, Gao Y, Baldwin R, Zoghbi S, Neumeyer J. Synthesis of β-CIT-BAT, a potential technetium-99m imaging ligand for dopamine transporter. Tetrahedron Letters 1996, 37: 4353-4356. DOI: 10.1016/0040-4039(96)00826-x.
ChemInform Abstract: N‐Substituted Analogues of 2β‐Carbomethoxy‐3β‐(4′‐iodophenyl) tropane (β‐CIT) with Selective Affinity to Dopamine or Serotonin Transporters in Rat Forebrain.NEUMEYER J, TAMAGNAN G, WANG S, GAO Y, MILIUS R, KULA N, BALDESSARINI R. ChemInform Abstract: N‐Substituted Analogues of 2β‐Carbomethoxy‐3β‐(4′‐iodophenyl) tropane (β‐CIT) with Selective Affinity to Dopamine or Serotonin Transporters in Rat Forebrain. ChemInform 1996, 27: no-no. DOI: 10.1002/chin.199619250.
N-Substituted Analogs of 2β-Carbomethoxy-3β-(4‘-iodophenyl)tropane (β-CIT) with Selective Affinity to Dopamine or Serotonin Transporters in Rat ForebrainNeumeyer J, Tamagnan G, Wang S, Gao Y, Milius R, Kula N, Baldessarini R. N-Substituted Analogs of 2β-Carbomethoxy-3β-(4‘-iodophenyl)tropane (β-CIT) with Selective Affinity to Dopamine or Serotonin Transporters in Rat Forebrain. Journal Of Medicinal Chemistry 1996, 39: 543-548. PMID: 8558525, DOI: 10.1021/jm9505324.
ChemInform Abstract: An Efficient Synthesis of m‐Hydroxycocaine and m‐ Hydroxybenzoylecgonine, Two Metabolites of Cocaine.TAMAGNAN G, GAO Y, BAKTHAVACHALAM V, WHITE W, NEUMEYER J. ChemInform Abstract: An Efficient Synthesis of m‐Hydroxycocaine and m‐ Hydroxybenzoylecgonine, Two Metabolites of Cocaine. ChemInform 1995, 26: no-no. DOI: 10.1002/chin.199548233.
An efficient synthesis of m-hydroxycocaine and m-hydroxybenzoylecgonine, two metabolites of cocaineTamagnan G, Gao Y, Bakthavachalam V, White W, Neumeyer J. An efficient synthesis of m-hydroxycocaine and m-hydroxybenzoylecgonine, two metabolites of cocaine. Tetrahedron Letters 1995, 36: 5861-5864. DOI: 10.1016/0040-4039(95)01178-k.

Edit Profile

Contact Information

Research & Publications

Biography

News

Coauthors

Selected Publications